Alamar Biosciences, Inc. ALMR
Clears both ethical standardsAn entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases.
read at $33.12
Alamar Biosciences, Inc. sits unlabelled at $33.12. The next dated read will name it.
- PHPhase · no phase label on file yet
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · passes the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Unlabelled |
| Price | $33.12 |
| Valuation | N/A trailing · -61.06 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | N/A |
The opportunity · what the numbers say it is worth
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our model and the Street both land near today's price — fairly valued, with no strong edge either way.
| Revenue growth | 82.10% |
| Profit margin | -49.45% |
| Debt to equity | 16.43 |
| Analyst consensus | None · 5 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
Used by most halal investing apps ✓ PASSES
The one Titan applies ✓ PASSES
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is just 29.6% of its assets, well under the one-third ceiling — it does not run on borrowed money. Pass
- Interest-bearing cash Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
- Receivables Money owed to the company is 30.5% of assets, under the 49% limit. Pass
- Revenue purity Only 2.9% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Early disease detection sounds promising but stays unproven
Imagine a blood test that spots disease proteins years before symptoms appear. Alamar Biosciences is racing to build that with its NULISA platform, selling instruments and consumables into a market hungry for better diagnostics. Revenue is doubling each year at 99 percent, the shares trade below our calculated fair value, and the business clears our ethical screen without issue.
Yet the numbers still give pause. Margins sit at minus 50 percent, the forward multiple is deeply negative, and no clear moat protects the technology from larger rivals. Five analysts call it a buy with a 32 dollar median target, but that optimism rests on forecasts that have yet to turn into sustained profits.
High growth in medical tools often masks how long it takes to reach scale and steady cash flow. We therefore pass. Analysis, not advice.
| Forward P/E | -61.1x |
| Revenue growth | 82.1% growing very fast |
| Profit margin | -49.5% currently unprofitable |
| Debt to equity | 0.16 minimal debt — a conservative balance sheet |
| Current ratio | 11.85 comfortably covers its short-term bills |
| Market cap | $2.3B |
| Employees | 222 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in ALMR's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
ALMR trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $23.88 | -10.5% | · | $895 | -10.5% |
Historical returns from market close data. Past performance does not guarantee future results.